PAR-23-076: NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 18, 2025.
From the official notice on Grants.gov, last changed January 12, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeP50
- Clinical trialsOptional
- Funded byNIDA
- Median yearly award$358,348
- Typical project length4.5 years
- P50, Specialized Center Grant. A research center on one disease or topic, with several projects and shared cores. Other open P50 notices.
Projects funded under PAR-23-076 were run by National Institute on Drug Abuse (NIDA, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-23-076 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-22-133 | March 14, 2022 | Closed January 12, 2023 | Closed |
Key dates
| Posted | January 12, 2023 |
|---|---|
| Deadline | November 18, 2025 |
| Archived by Grants.gov | December 24, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDAs mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are required. The P50 Center of Excellence is expected to foster the career development and mentoring of new investigators who would be given meaningful roles to play in the Center projects. A goal of this program is to create NIDA Centers that are national community resources for furthering drug abuse research by sharing their findings, their data, and their resources as appropriate for researchers to use and build upon and to advance research in this field.
Funded under PAR-23-076 so far
NIH funded 5 projects under PAR-23-076 in fiscal 2024 to 2026, at 5 institutions. The median yearly award was $358,348.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Subject Management and Biobanking | University of Pittsburgh at Pittsburgh | 2026 | $477,161 |
| Novel secondary data analysis methods for building knowledge about adaptive SUD services that integrate human- and digitally- delivered components | University of Michigan at Ann Arbor | 2026 | $243,196 |
| Behavioral Phenotyping Core | University of California, San Diego | 2026 | $352,002 |
| P1 - OPEN | Oregon Health & Science University | 2026 | $358,348 |
| Impact of Cannabinoid Across the Lifespan (ICAL) | University of California-Irvine | 2026 | $52,245 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-23-076 still open?
No. It closed on November 18, 2025.
Who can apply for NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)?
Closed November 18, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-23-076?
NIH RePORTER lists 5 projects funded under PAR-23-076 in fiscal 2024 to 2026, at 5 institutions. The most were at University of Pittsburgh at Pittsburgh, University of Michigan at Ann Arbor, University of California, San Diego.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- NIH Specialized Center Grant (Parent P50)
- National Biomedical Research Centers (P50 Clinical Trial Optional)
- Specialized Alcohol Research Centers (P50 Clinical trial Optional)
- Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)